PMID- 30964192
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 23
IP  - 6
DP  - 2019 Mar
TI  - Combination of cells-based therapy with apelin-13 and hyperbaric oxygen 
      efficiently promote neovascularization in ischemic animal model.
PG  - 2630-2639
LID - 17413 [pii]
LID - 10.26355/eurrev_201903_17413 [doi]
AB  - OBJECTIVE: Critical lower-limb ischemia (CLLI) is characterized by high morbidity 
      and mortality. The aim of this study was to explore the effectiveness of the 
      combination of cell therapy with apelin-13 and hyperbaric oxygen in CLLI animal 
      model. MATERIALS AND METHODS: The experimental ischemic rats were divided into 
      five groups, including negative control, bone marrow derived mononuclear cells 
      (BM-MNCs), apelin-13, hyperbaric oxygen treatment (HBOT) and apelin-13 with HBOT 
      group. Each group was composed of 10 rats. Endothelial progenitor cells (EPCs) 
      derived from bone marrow were transplanted into the ischemia rat model. After 3 
      weeks of transplantation, the formation of new vessels was evaluated by examining 
      cluster of differentiation (CD)31, CD34 and vascular endothelial growth factor 
      receptor 2 (VEGFR-2) expressions as well as a direct vision of vessels by 
      hematoxylin and eosin (HE) staining and immunohistochemistry. RESULTS: Compared 
      with the negative control group, both angiogenic factors expressions and the 
      number of new vessels increased notably by the transplantation of BM-MNCs in the 
      ischemic models. Apelin-13 or HBOT alone improved the efficacy within limit while 
      the combination of the three elements remarkably promoted the neovascularization 
      in ischemic limbs. CONCLUSIONS: BM-MNC induced angiogenesis in the ischemic limbs 
      and was considered an effective resource for cell therapy. The preliminary data 
      of this study showed that the combination of cell therapy with apelin-13 and HBOT 
      improved the efficacy of angiogenesis.
FAU - Yu, M
AU  - Yu M
AD  - Department of Vascular Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China. tyf224@163.com.
FAU - Yuan, H-S
AU  - Yuan HS
FAU - Li, Q
AU  - Li Q
FAU - Li, Q
AU  - Li Q
FAU - Teng, Y-F
AU  - Teng YF
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antigens, CD34)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
RN  - 0 (apelin-13 peptide)
RN  - EC 2.7.10.1 (Kdr protein, rat)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Animals
MH  - Antigens, CD34/metabolism
MH  - Combined Modality Therapy
MH  - Disease Models, Animal
MH  - Endothelial Progenitor Cells/metabolism/*transplantation
MH  - Gene Expression Regulation
MH  - Hindlimb/*blood supply
MH  - Hyperbaric Oxygenation
MH  - Intercellular Signaling Peptides and Proteins/*pharmacology
MH  - Ischemia/metabolism/*therapy
MH  - Male
MH  - Neovascularization, Physiologic
MH  - Platelet Endothelial Cell Adhesion Molecule-1/metabolism
MH  - Rats
MH  - Vascular Endothelial Growth Factor Receptor-2/metabolism
EDAT- 2019/04/10 06:00
MHDA- 2020/08/26 06:00
CRDT- 2019/04/10 06:00
PHST- 2019/04/10 06:00 [entrez]
PHST- 2019/04/10 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
AID - 17413 [pii]
AID - 10.26355/eurrev_201903_17413 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2630-2639. doi: 
      10.26355/eurrev_201903_17413.